跳至主要内容
临床试验/NCT00006020
NCT00006020已完成2 期

A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-cell Acute Lymphoblastic Leukemia (ALL)

SWOG Cancer Research Network213 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2000年7月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
35
试验地点
213
主要终点
CR

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory acute lymphocytic leukemia.

详细描述

OBJECTIVES:

  • Assess the complete remission rate in patients with recurrent or refractory non-T-cell acute lymphocytic leukemia when treated with 506U78.
  • Determine the frequency and severity of toxic effects of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every month for 6 months, every 3 months for 1 year, and then every 6 months for 3.5 years.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

CR

时间窗: After induction therapy is completed

次要结局

未报告次要终点

研究者

申办方类型
Network
责任方
Sponsor

研究点 (213)

Loading locations...

相似试验

S0010 506U78 in Treating Patients With Recurrent or... | 临床试验